Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Boehringer Pens €1.05B Deal for Simcere's Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim signs €1.05B deal for Simcere’s SIM0709, a bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease.
China Clears Huahui Health’s Libevitug as First Drug for Chronic Hepatitis D
Huahui Health wins NMPA approval for libevitug, China's first drug for chronic hepatitis D, plugging a major gap in treatment options.
Trial of Myeloma Therapy KLN-1010 Gets FDA Green Light to Expand to US
Phase 1 inMMyCAR trial for myeloma therapy KLN-1010 expands to US. Kelonia Therapeutics testing genetic therapy in relapsed or refractory patients.
Aclaris ATI-2138 Shows Rapid Hair Regrowth in Alopecia Areata Model
Aclaris’ ITK/JAK3 inhibitor ATI-2138 showed rapid hair regrowth in a murine alopecia model, outperforming ritlecitinib.
MSD Ends Takeover Talks with Revolution Medicines Over Price
MSD ends talks to acquire Revolution Medicines after failing to agree on price. Deal was valued at $28bn-$32bn. Revolution market cap is $23bn.
Cancer Tumors May Protect Against Alzheimer's by Cleaning Protein Clumps
Study finds cancer tumors secrete Cystatin-C protein to clean amyloid clumps in Alzheimer's brains, activating microglia to reverse damage.
Enzyme-Blocking Treatment Reverses Chronic Pain in Preclinical Study
Virginia Tech scientists found blocking an enzyme system reverses nociplastic chronic pain in mice, offering a potential new non-opioid treatment.
IGC Pharma Adds New York Site for CALMA Phase II Alzheimer’s Disease Trial
IGC Pharma expands CALMA Phase II trial for IGC-AD1 in Alzheimer’s agitation by adding Integrative Clinical Trials in New York to its network.
BMS Signs $850m Deal with Janux for Novel Solid Tumour Therapy
BMS signs $850m deal with Janux for solid tumour therapy to bolster oncology pipeline amid Opdivo and Eliquis patent expiries.
Corcept Stock Rises as Relacorilant Meets OS Goal in Phase III Ovarian Cancer
Corcept stock rose 14% after relacorilant met overall survival goal in the Phase III ROSELLA trial for platinum-resistant ovarian cancer.
Olatec Presents Preclinical Evidence of Dapansutrile Activity in Parkinson's
Olatec Therapeutics presented preclinical data showing dapansutrile produces disease-modifying effects in Parkinson's disease models at MJFF forum.
Shionogi Expands ViiV Healthcare Stake to 21.7% as Pfizer Exits
Shionogi invests $2.13bn in ViiV Healthcare, increasing stake to 21.7%. Pfizer sells its 11.7% interest. GSK retains majority 78.3% stake.
32
33
34
35
36
37
38
39
40
